Targeting the B Cell Response to Treat Antibody-Mediated Rejection

靶向 B 细胞反应来治疗抗体介导的排斥反应

• 批准号: 10636822
• 负责人: Stuart Johnston Knechtle
• 金额: $ 258.25万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-20 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10636822
• 关键词: Affect; Allogenic; Allografting; American; Antibodies; Antibody Therapy; Antibody-Producing Cells; Arteritis; B cell therapy; B-Cell Activation; B-Lymphocytes; Binding; Biological Assay; Biopsy; Cell Communication; Cell Compartmentation; Cell physiology; Cells; Chronic; Clinical; Cluster Analysis; Conduct Clinical Trials; Controlled Study; Cytomegalovirus; Data; Diagnosis; Dialysis procedure; End stage renal failure; Ensure; Ethics; Failure; Graft Survival; Half-Life; Healthcare; Heart Transplantation; Hemodialysis; Histologic; Human; Image Analysis; Immune; Immune Targeting; Immune system; Immunity; Immunologics; Infection; Inflammation; Injury; Intervention; Intervention Studies; Intravenous Immunoglobulins; Investigational Therapies; Isoantibodies; Kidney; Kidney Transplantation; Level of Evidence; Life; Longevity; Lung Transplantation; Lymphocyte Activation; Malignant Neoplasms; Measures; Mediating; Memory; Memory B-Lymphocyte; Methods; Modeling; Monitor; Organ Donor; Organ Transplantation; Outcome; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Phase; Phase I/II Clinical Trial; Plasma Cells; Plasmablast; Plasmapheresis; Population; Predisposition; Prevention; Process; Prognosis; Proteasome Inhibition; Proteasome Inhibitor; Proteinuria; Public Health; Randomized; Reaction; Regimen; Renal function; Resistance; Risk; Risk Assessment; Safety; Solid; Standardization; Structure of germinal center of lymph node; Surrogate Markers; System; T-Lymphocyte; Testing; Therapeutic Uses; Time; Transplant Recipients; Transplantation; Treatment Efficacy; Tubular formation; United States; Visual; antibody-mediated rejection; care costs; comparison control; deep learning; desensitization; digital; digital imaging; donor-specific antibody; effective therapy; experience; health goals; human data; improved; improved outcome; infection risk; interstitial; kidney biopsy; machine learning algorithm; mortality; nonhuman primate; novel; pathogen; post-transplant; predict clinical outcome; predicting response; prevent; prospective; public health relevance; response; restoration; retransplantation; rituximab; targeted treatment; tool; treatment comparison; treatment response; whole slide imaging

ABSTRACT Antibody-mediated rejection (AMR) of solid organ transplants is the leading cause of immunologic graft injury, shortening the half-life of transplants and consequently of transplant recipients. This immunologically mediated process depends on B lymphocyte activation with differentiation to plasma cells (PC) that produce antibodies to the donor organ. Once established, antibodies have proven difficult to eradicate. Establishing an effective and safe way to treat patients with established AMR would potentially increase the half-life of transplanted organs, extend the lives of patients, and reduce the need for re-transplantation, ultimately increasing the number of patients who could receive life-saving organ transplants. Our lab has described an effective therapy in a non- human primate (NHP) sensitized model of kidney transplantation for lowering donor-specific antibody (DSA) and preventing injury from AMR. The treatment depends on PC depletion in combination with germinal center disorganization which together lower alloantibody levels. Dual targeting of the immune system by complementary drugs is based on NHP and human data using a proteasome inhibitor and belatacept. B cell activation and differentiation is inhibited at the same time that PC are depleted. Consequently, DSA declines, inflammation in the kidney resolves, and renal function stabilizes. The impact of this intervention on infection risk is not well defined but is anticipated to increase. We propose to measure the impact of therapy on both HLA-specific and pathogen-specific B memory cells and PC. We hypothesize that there is a hierarchy of susceptibility to therapy, with protective immunity being more resistant than allogeneic B cell memory. We will evaluate the impact of the regimen on T-cell function focusing on cytomegalovirus (CMV). Current therapy of late AMR using therapeutic plasma exchange (TPE) and intravenous immune globulin (IVIG) with or without rituximab has shown variable results and frequent rebound of DSA. A low level of evidence supports the efficacy of these treatments, implying a tremendous need for well-conducted clinical trials to guide treatment of AMR. We propose a Phase I/II randomized, controlled, prospective interventional study of AMR in human kidney transplant patients using combined carfilzomib/belatacept (C/B) therapy with TPE and IVIG compared to TPE/IVIG alone. Outcomes will include the clinical impact of therapy on AMR using the recently validated iBox score for AMR assessment and the number and type of infections using standardized definitions of infection. We will measure the impact of therapy on HLA and pathogen-associated B memory and PC as well as CMV-specific polyfunctional T-cells. We will assess computational digital imaging analysis of AMR non-visual biopsy features to assess whether machine learning algorithms can improve on Banff criteria of AMR to better guide treatment and predict clinical outcome. Since late active and chronic active AMR have such a poor prognosis for kidney transplant patients, we believe that this trial is ethically justified and would potentially yield important safety and preliminary efficacy data that may lead to improved immune management of transplant patients.

抽象的 固体器官移植的抗体介导的排斥（AMR）是免疫移植损伤的主要原因， 缩短移植的半衰期以及移植受者的。这种免疫学介导的 过程取决于B淋巴细胞激活，并分化与浆细胞（PC），产生抗体的抗体 捐赠器官。一旦建立，抗体就被证明难以根除。建立有效和 安全治疗已建立AMR的患者的安全方法可能会增加移植器官的半衰期，即 延长患者的寿命，并减少重新转移的需求，最终增加 可以接受挽救生命器官移植的患者。我们的实验室描述了一种有效的疗法 人类灵长类动物（NHP）的肾移植模型，用于降低供体特异性抗体（DSA）和 防止AMR受伤。治疗取决于PC耗竭与生发中心的结合 混乱，共同降低同种异体抗体水平。通过补充对免疫系统的双重靶向 药物使用蛋白酶体抑制剂和BELATACEPT基于NHP和人类数据。 B细胞激活和 在PC耗尽的同时抑制了分化。因此，DSA下降，发炎 肾脏消退，肾功能稳定。这种干预对感染风险的影响不好 定义但预计会增加。我们建议衡量治疗对HLA特异性和 病原体特异性B存储单元和PC。我们假设存在对治疗易感性的层次结构， 保护性免疫比同种异体B细胞记忆更具耐药性。我们将评估 针对巨细胞病毒（CMV）的T细胞功能方案。当前使用治疗的AMR治疗 有或没有利妥昔单抗的血浆交换（TPE）和静脉免疫球蛋白（IVIG）显示出可变的 结果和频繁的DSA反弹。低水平的证据支持这些治疗的功效，这意味着 对指导AMR治疗的良好进行临床试验的巨大需求。我们提出了I/II期 使用人类肾脏移植患者中AMR的随机，受控，前瞻性介入研究 与单独使用TPE/IVIG相比，Carfilzomib/Belatacept（C/B）疗法与TPE和IVIG相比。结果会 使用最近经过验证的ibox评分进行AMR评估，包括治疗对AMR的临床影响 使用标准化感染定义的感染数量和类型。我们将衡量 HLA和病原体相关的B记忆和PC以及CMV特异性多功能T细胞的治疗。我们 将评估AMR非视觉活检特征的计算数字成像分析，以评估是否机器 学习算法可以改善AMR的班夫标准，以更好地指导治疗并预测临床结果。 由于晚期活性和慢性活动的AMR对肾脏移植患者的预后较差，我们认为 该试验在道德上是合理的，并有可能产生重要的安全性和初步疗效数据 可能会改善移植患者的免疫治疗。